Every letter we have printed

I stopped at week six because I could not keep anything down for three days, and my prescriber told me I had not given it a fair chance. Reading your definition of dose-limiting, I think what happened was that nobody offered me the option of going back to the lower dose. It was escalate or stop.

As an anaesthetist I read the perioperative section with interest and one objection. You frame disclosure as the patient obligation. In my experience the failure is more often ours: the pre-assessment questionnaire in my own institution did not include these drugs until eighteen months after the first guidance appeared.

You give the reference change value for ALT as about sixty per cent, which strikes me as so large as to make routine monitoring of it pointless. Is that your position?

Correction to your HbA1c section. You write that chronic kidney disease lowers HbA1c through shortened erythrocyte survival. It can also raise measured values on some assay platforms through carbamylated haemoglobin interference. The net direction depends on the method.

I stopped treatment fifteen weeks ago and my panel is worse than I expected. I had a panel at five weeks that looked fine and I had assumed I had escaped. Your point about the twelve-week timing was the explanation nobody offered me.

My eGFR has risen from 71 to 84 over fourteen months of treatment and I have lost twenty-six kilograms. My prescriber described this as the drug protecting my kidneys. Having read your creatinine section, I suspect it is mostly that I have less muscle. Which of us is right?

On the accreditation-scope point: most private buyers will not know which accreditation body to search. It would be more useful to publish the four or five registers that cover the laboratories this market actually uses than to tell readers the registers exist.

I have a certificate with an expiry date twenty-four months from manufacture and no stability data behind it, which your article says is a claim the documentation cannot support. The supplier tells me it is industry standard. Is it?

Your ten-minute check told me in about ninety seconds that the batch number on my certificate appears nowhere on the vial. I wrote to the supplier and had a straightforward answer within a day: the certificate covers the bulk lot and the vial carries a fill code. I would never have known to ask.

You describe reused chromatogram images as a tell. I work in a contract laboratory and I would note that some data systems export a representative overlay rather than the individual injection, so identical-looking traces can occur legitimately across a batch series. It is still worth asking about; it is not the smoking gun your article implies.

I have read three separate articles this month describing cagrilintide as a GLP-1 agonist and one describing tirzepatide as "semaglutide with an extra bit". Thank you for the glossary. Please run it again.

The claim that nothing at baseline predicts response is too strong. Surely baseline BMI, sex and diabetes status shift the expected outcome — the trials stratify on exactly those variables.

As a community pharmacist I would add one thing to your section on missed doses: the label window matters less than whether the patient then double-doses to "catch up". I have seen that twice this year and both times the patient believed they were following instructions.

Your table of degradation pathways lists racemisation and then says it is essentially never reported. If it is never reported, on what basis do you list it as a real risk rather than a theoretical one?

I run a small analytical laboratory and I want to defend the twelve-minute method. It is fit for the purpose it is sold for: confirming that a sample is broadly what it claims to be, at a price a private buyer will actually pay. The problem is not the method. It is suppliers printing its output as though it were a release specification.

Why anonymise the four services? Naming them is the only way a reader can act on this.

Your point about the 280 nm wavelength is the most useful thing I have read this year. I checked the four certificates in my drawer and two of them read at 280.

You describe biased agonism as "legitimate and probably important" and then decline to say which molecules are biased in which direction. That is a strange place to stop.

I found the section on the area postrema genuinely clarifying. I had assumed nausea was a stomach problem and had been treating it as one, unsuccessfully, for four months.

Your accumulation table gives 2.0 for a seven-day half-life at weekly dosing. I make it 2.0 as well, but I would point out that this assumes complete absorption of each dose, which for subcutaneous peptides is a generous assumption.

As a community pharmacist I would add one thing to your section on missed doses: the label window matters less than whether the patient then double-doses to "catch up". I have seen that twice this year and both times the patient believed they were following instructions.

You spend a page on the four-line calculation and then publish a reconstitution table anyway. Are you not providing exactly the pre-computed number you warned against?

A quibble on your dead-space figure. You give two to seven microlitres for insulin-type needles, which is right for fixed-needle syringes, but the detachable pen needle plus syringe hub combinations sold in this market are considerably worse and you should say so.

I gave myself a tenth of my intended dose for five weeks. I had been using insulin syringes, ran out, and used the 1 mL syringes that came with the vials, which are marked in millilitres. I did not notice because the plunger was in roughly the same place. Nobody warned me these were different scales.

You keep insisting on peptide content rather than purity when discussing dose certainty. I have looked at a dozen certificates from four different testing services and content is reported on perhaps a third of them. What are readers supposed to do with an absence?

Your piece treats the four-week step as arithmetic, and I accept the arithmetic, but my prescriber moved me up every two weeks and I reached the top dose without difficulty. I do not think the schedule is as constraining as you suggest.

The price table is the most useful thing you have published this year and also the thing most likely to be quoted out of context by somebody selling a comparison service. You might consider a note.

Small correction to your table: the S-LiTE exercise prescription was two supervised group sessions and two individual sessions weekly, not two sessions in total. The distinction matters because "add some exercise" is not what was tested.

I am sixty-eight, I have lost nineteen kilograms over fourteen months, and my consultant has twice told me my lean mass is fine on the basis of a handheld bioimpedance device in the clinic corridor. Having read your piece on what that device measures, I am no longer sure what I have been reassured about.

Your piece treats the one-quarter rule as discredited and then quotes fractions of one third and two fifths from the substudies as though those were more solid. They are group means from a hundred and forty people. Physician, heal thyself.

I train four times a week, eat a hundred and sixty grams of protein and my appendicular lean mass has fallen by 1.8 kg over ten months while every lift has gone up. Your section on mass against function was the first thing I have read that made that seem normal rather than a failure.

As a DXA technologist of twenty-two years I would add one thing to your precision section: the largest source of error in practice is not the machine, it is positioning. A patient scanned with their arms two centimetres further from their trunk will report different regional values. We are trained to a protocol and the protocol is not always followed.

A small point of precision. You use "gastroparesis" in the tag list and then spend a paragraph saying it is not a synonym for drug-induced emptying delay. That is a slightly awkward position to hold.

I stopped eight months ago after reaching a weight I was happy with, and I have regained four of the twenty-two kilograms I lost. Every article I read told me to expect two-thirds back. I am not complaining, but I would like to know whether I am unusual or whether the two-thirds figure was always a mean concealing an enormous range.

You describe the maintenance strategy of stepping down one dose and holding for eight to twelve weeks as something clinicians report doing, and then say it is not a recommendation. That distinction will be lost on most readers, and printing the protocol makes you a source for it whether you intend to be or not.

I lost access for eleven weeks during the shortage, restarted at the dose I had been on because nobody told me otherwise, and spent a fortnight unable to keep food down. I had been on that dose for seven months without difficulty. Reading your resumption section was the first time anybody explained it.

Your piece describes tapering as pharmacologically pointless and then spends three paragraphs making a case for it. Pick one.

You say no dose-equivalence data exists between agents in this class. During the shortage my pharmacy substituted one for another on the basis of a conversion table they had printed from somewhere. Where would such a table have come from?

The claim that nothing at baseline predicts response is too strong. Surely baseline BMI, sex and diabetes status shift the expected outcome — the trials stratify on exactly those variables.

I have read three separate articles this month describing cagrilintide as a GLP-1 agonist and one describing tirzepatide as "semaglutide with an extra bit". Thank you for the glossary. Please run it again.